Sunday, September 27, 2026

Moderna Stock Bearish By 3% At Session Start On Tuesday

ViaNews Editorial Team

December 15, 2020

Moderna Stock Bearish By 3% At Session Start On Tuesday

Shares of Moderna fell 3.99% to $148.88 at 10:09 EST on Tuesday, following yesterday's upward trend. The Nasdaq Stock Market is jumping 0.5% to $12,440.00, following yesterday's upward trend, This seems, as yet, a somewhat positive trend exchanging session today.

Moderna's last close was $156.93, 19.90% under its 52-week high of $178.50.

News about Moderna today

Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to today's article on The Wall Street Journal, "-Shares of the vaccine maker Moderna were down 1% premarket. "

Moderna vaccine found safe, effective ahead of key FDA review. According to today's article on Bloomberg Quint, "Moderna's vaccine isn't yet approved in any other countries and hasn't yet been used on anyone outside of a clinical trial.", "Between Pfizer and Moderna, Operation Warp Speed officials have said 20 million people in the U.S. are expected to get their first shots by year-end."

Moderna vaccine found safe, effective before key FDA review. According to today's article on Bloomberg Quint, "In addition, there were two cases of serious facial swelling in vaccine recipients that Moderna determined were related to vaccination. ", "The FDA got a much deeper look at Moderna's clinical-trial data than the numbers previously released to the public by the company. "

Moderna shares up in premarket as FDA calls covid-19 vaccine 'highly effective'. According to today's article on MarketWatch, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company's COVID-19 vaccine candidate is "highly effective" at preventing infections with the coronavirus. "

Moderna's Sales

Moderna's sales growth is 1428.1% for the current quarter and 13065.3% for the next. The company's growth estimates for the ongoing quarter is a negative 48.6% and positive 565.7% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is valued at $148.88 at 10:09 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is way above its 50-day moving average of $104.71 and way above its 200-day moving average of $77.26.

Previous days news about Moderna

Moderna offers U.S. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, "Moderna's shot is expected to go before the same panel on Dec. 17th.", "Moderna Inc. could offer a fail-safe option that will allow the U.S. to get enough Covid-19 shots to inoculate most Americans if the government can't reach an agreement to quickly buy more vaccine from Pfizer Inc., which plans to honor its contracts with other countries."

Moderna says U.S. to buy 100 million additional vaccine doses. According to Bloomberg Quint on Fri Dec 11, "Read More: Moderna Offers U.S. Fail-Safe on Vaccines If Pfizer Falls Short", "As part of Operation Warp Speed, the U.S. initiative to rapidly develop and secure vaccines for Covid-19, the U.S. has the option to buy another 300 million doses from Moderna at a fixed price of $16.50 per shot, the company said. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com